Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Change in Urine Albumin Excretion
研究概览
简要总结
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with diabetes mellitus and early kidney disease. Eligibility criteria include type 2 diabetes and stage 1-2 chronic kidney disease, defined by a urine albumin-creatinine ratio 30-300 mg/g and an estimated glomerular filtration rate ≥ 60 mL/min. Participants will be randomly assigned to treatment with vitamin D3 or placebo, each taken by mouth once daily for a study duration of one year. Study medications will be added to standard treatment, including an angiotensin converting enzyme inhibitor and/or angiotensin II receptor blocker. We hypothesize that vitamin D3, compared with placebo: (1) is well-tolerated and safe among people with diabetes and kidney disease; (2) results in adequate attained circulating vitamin D levels; and (3) positively affects markers of kidney disease and cardiovascular risk.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of type 2 diabetes mellitus
- •Urine albumin-creatinine ratio 30-1000 mg/g
- •Estimated glomerular filtration rate greater than or equal to 60 mL/min
- •Treatment with angiotensin converting enzyme inhibitor and/or angiotensin II receptor blocker for greater than or equal to 6 months, with a stable dose for greater than or equal to 3 months
- •Blood pressure less than 140/90 (assessed while taking medications)
- •Hemoglobin A1c less than 9% (assessed while taking medications)
- •25-hydroxyvitamin D less than 30 ng/mL
排除标准
- •Prior dialysis or kidney transplantation
- •Known cause of albuminuria other than diabetes
- •Planning to leave the area within 12 months
- •Life expectancy less than 12 months
- •Participation in another clinical trial within 6 months
- •Osteoporosis or other established indication for vitamin D therapy
- •Vitamin D3 supplement intake greater than 400 IU/day at screening visit
- •History of nephrolithiasis
- •Serum calcium greater than 10.2 mg/dL
- •Dementia, not fluent in English, or unable to provide informed consent without proxy respondent
- •Incontinent of urine
- •Failure to take greater than or equal to 80% of placebo pills during study run-in
结局指标
主要结局
Change in Urine Albumin Excretion
时间窗: Baseline, 3 months, and one year
Albumin and creatinine concentrations were measured in 24hr urine collections at baseline, 3 months after randomization, and one year after randomization. We analyzed the difference in log-transformed albumin-creatinine ratio (ACR, mg/g) after randomization (3 months and one year, analyzed together with all available data included) compared with baseline, by treatment assignment. Results are transformed to present percent difference in urine ACR.
次要结局
未报告次要终点
研究者
Ian deBoer
Study Principal Investigator
University of Washington